Frida Persson
AstraZeneca
5 Papers
40 Citations
Frida Persson is an academic researcher from AstraZeneca. The author has contributed to research in topics: hERG & Antiarrhythmic agent. The author has an hindex of 5, co-authored 5 publications.
Chat about Author
Papers
Mechanism of Action of the Antiarrhythmic Agent AZD7009
TL;DR: AZD7009 delays repolarisation and increases refractoriness in atrial tissue through synergistic inhibition of IKr, Ito, IKur and INa, a mixed ion channel blockade that may underlie its high antiarrhythmic efficacy.
75
Functional effects of the late sodium current inhibition by AZD7009 and lidocaine in rabbit isolated atrial and ventricular tissue and Purkinje fibre.
TL;DR: Excessive action potential duration prolongation induced by E-4031 was attenuated by AZD7009 and lidocaine in rabbit Purkinje fibre, but not in atrial or ventricular tissue, most likely by inhibiting the late sodium current.
58
Blocking characteristics of hKv1.5 and hKv4.3/hKChIP2.2 after administration of the novel antiarrhythmic compound AZD7009.
TL;DR: The main objective of the present study was to characterize the effects of AZD7009 on hKv1.5 and hKV4.3/hKChIP2.2 currents to get a deeper understanding of the ion channel-blocking properties of the compound.
31
Lactam sulfonamides as potent inhibitors of the Kv1.5 potassium ion channel
Roine I. Olsson,Ingemar Jacobson,Tommy Iliefski,Jonas Boström,Öjvind Davidsson,Ola Fjellström,Annika Björe,Christina Olsson,Johan Sundell,Ulrik Gran,Jonna Gyll,Jesper Malmberg,Olle Hidestål,Hans Emtenäs,Tor Svensson,Zhong-Qing Yuan,Gert Strandlund,Annika Åstrand,Emma Lindhardt,Gunilla Linhardt,Elin Forsström,Ågot Högberg,Frida Persson,Birgit Andersson,Anna Rönnborg,Boel Löfberg +25 more
TL;DR: In vitro structure-activity relationships from lead structure C to optimized structure 3y were described and compound 3y was found to selectively prolong the atrial effective refractory period at submicromolar concentrations.
9
Blocking Characteristics of hERG, hNav1.5, and hKvLQT1/hminK after Administration of the Novel Anti-Arrhythmic Compound AZD7009
TL;DR: The main aim of this study was to characterize the blocking effects of AZD7009 on the human ether‐a‐go‐ go‐related gene (hERG), the hNav1.5, and the hKvLQT1/hminK currents.